Injection-Related Risks With Injectable GHK-Cu FDA identifies compounded injectable drugs containing GHK-Cu as a potential immunogenicity risk because of aggregation and peptide-related impurities, and FDA notes limited human data to inform safety considerations [8]
At 12 months, significant HbA1c changes from baseline were found in both treatments (dulaglutide: 1.06%, p upper normal limit [UNL], UNL), and body mass index ( 27 kg/m 2 , UNL), the ALT levels in both treatment groups significantly declined at 12 months (i.e., dulaglutide: 19.13 U/L [SD: 36.31] and liraglutide: 22.79 U/L [41.85], p UNL versus UNL) (Additional file 1: Appendix Figure S2d)
Martinelli, C
During perimenopause, hormones fluctuate sharply, so supplements that stabilize estrogen and cortisol are especially helpful
This variability means your blood work changes might be less predictable
One of the biggest challenges in all of this is getting a successful remediation done, she said